


# N3C



# National Covid Cohort Collaborative update

NCATS CTSA Steering Committee
January 11th, 2021







## **N3C Enclave Data Stats**

# Over Two Billion Rows 2.5 Million Patients

COVID-19 Positive Patients\*

413,228

**Total Patients** 

2,509,112

Sites

36

Total Rows

2.6b

**Procedures** 

185.6m

Lab Results

1.1b

**Drug Exposures** 

472.9m


**Visits** 

134.1m

Observations

185.5m





	Mild		Hospitalized			All COVID positive	Hospitalized
	outpatient (no ED)	ED	Moderate	Severe	Mortality/ Hospice	,	=-
N	121,078	21,018	25,907	2,790	3,775	174,568	32,472
Diabetes Mellitus		10.9%	24.5%	27.4%	34.0%	11.0%	25.9%
Renal Disease		3.5%	13.6%	13.3%	25.8%	4.8%	15.0%
Congestive Heart Failure		2.5%	11.2%		22.1%	3.7%	12.4%
Chronic Pulmonary Disease	7.0%	10.4%	16.6%	14.0%	21.4%	9.2%	17.0%
Peripheral Vascular Disease		4.0%	10.7%	8.7%	18.4%	4.4%	11.5%
Stroke		2.8%	8.9%	8.4%	16.8%	3.3%	9.8%
Cancer		3.4%	9.3%		15.3%	4.3%	9.8%
Dementia			4.0%		13.4%	1.3%	5.0%
Myocardial Infarction			5.4%		11.0%	1.9%	6.1%
Liver Disease		3.2%	6.4%		9.1%	3.0%	6.7%
Rheumatologic Disease		2.3%	4.0%		4.3%	2.3%	4.0%
Hemiplegia or Paraplegia			1.8%		3.4%		2.0%
Peptic Ulcer Disease			1.3%		2.3%		1.5%

#### **Cohort Characterization manuscript**

Predicting Clinical Severity using machine learning (64 input variables)

	Logistic Regression					
	Random	XG				
Variable	Forest	Boost	None	L1	L2	Me
pH	0	0	1	1	1	0
Age at visit start (years)	3	4	0	0	0	1.
Respiratory rate	7	3	2	2	2	3
Oxygen saturation (SpO2)	2	2	5	4	3	3. 5.
Systolic blood pressure (SBP)	9	8	4	3	5	5
Blood urea nitrogen (BUN)	1	1	11	11	10	6
Albumin	21	6	6	5	4	8
Lactate	18	9	7	7	7	9.
C-reactive protein (CRP)	16	11	8	8	8	10
Aspartate aminotransferase (AST)	6	5	12	22	18	12
Absolute neutrophil count	12	25	9	9	9	12
Ethnicity = missing or unknown	45	7	3	6	6	13
Glucose	5	18	16	15	14	13
Platelet count	10	22	14	13	13	14
Diastolic blood pressure (DBP)	13	15	21	17	16	16
B-type natriuretic peptide (BNP)	32	12	18	14	15	18
Sodium	15	27	15	18	17	18
Troponin	14	10	30	21	23	19
Erythrocyte sedimentation rate (ESR)	36	30	13	12	12	20
Sex = male	38	36	10	10	11	2
Body weight	19		19	16	19	24
Hemoglobin	17	51	24	20	21	26
Charlson Diabetes mellitus	37	24	25	27	24	27

The most powerful predictors are patient age and widely available vital sign and laboratory values.




## N3C team Science within & across institutions

#### **CTSAs**

# Key functions can nucleate projects:

- Education & training
- Biostatistics
- Study design
- Evaluation
- Informatics
- Clinical expertise
- Innovation & commercialization
- Community & partnerships



#### **N3C Domain Team Expertise:**

- Enclave technology
- Data model (OMOP)
- Terminologies
- Data quality
- Codesets, variables, phenotype
- Using/parsing N3C data
- Workflows, methods, algorithms

Roles
Ingredients (Methods, datasets, instruments)
Scientific questions

https://covid.cd2h.org/domain-teams



April 2020

# A Tsunami of Acute Kidney Injury

# The New York Times

An Overlooked, Possibly Fatal Coronavirus Crisis: A Dire Need for Kidney Dialysis

Ventilators aren't the only machines in intensive care units that are in short supply. Doctors have been confronting an unexpected rise in patients with failing kidneys.

f y m A



Miriam Figueroa, a dialysis nurse at the Brooklyn Hospital Center, tended to a patient in the intensive care unit on Thursday. Victor-

### A Life and Death Battle: 4 Days of Kidney Failure but No Dialysis

At the peak of the pandemic in New York, a longtime city employee joined a crush of patients in desperate need of treatment.



May 2020



## **Kidney Domain Team**





Stony Brook



Sandeep Mallipatu




**Richard Moffit** 



Farrukh Koraishy



Ivonne Schulman



#### PREMISE:

Kidney Injury contributes importantly to mortality and leads to long term mortality.

#### **QUESTIONS:**

What factors predict kidney injury early?
Are there regional differences in AKI incidence?
Is AKI incidence in COVID-19
decreasing?
What are the predictors of ESKD after AKI?

**Chirag Parikh** 





Faifan Liu



David H. Ellison



J. Brian Byrd



https://covid.cd2h.org/kidney/



## **N3C Upcoming Events**

Monday, Jan 11 <sup>th</sup>	9-11am PT/12-2pm ET	N3C Data Harmonization Symposium			
Tuesday, Jan 12 <sup>th</sup>	8am PT/11am ET	N3C Pilot Orientation Part A			
Friday, Jan 15 <sup>th</sup>	11-2pm PT/ 2-4 ET	N3C Nurses & Nurse Scientists Webinar			
Tuesday, Jan 19 <sup>th</sup>	9am PT/12pm ET	N3C Community Symposium & N3C Open House Week Jan 19th - 25th			
Tuesday, Jan 19 <sup>th</sup>	8am PT/11am ET	N3C Pilot Orientation Part B			
Monday, Feb 1st	9am PT/12pm ET	Trial Innovation Network (TIN) Collaboration Webinar - Using N3C Data to Inform your Protocol Development			

https://covid.cd2h.org/n3c-calendar

## Benefits to CTSA (and other) Organizations

- Access to large scale COVID-19 data from across the nation
- Pilot data for grant proposals
- Opportunities for KL2 and TL1 and other scholars
- Team science opportunities for new questions and access to Teams, statistics, machine learning (ML), informatics expertise
- Learn ML analytics, NLP methods & access to tools, software, additional datasets





# Help, Support & Training

N3C Support Desk page: <a href="https://covid.cd2h.org/help\_desk">https://covid.cd2h.org/help\_desk</a>

## Support Desk

View Edit Delete Layout Revisions

If you need assistance with the N3C Data Enclave, the following options are available:

- Attend Support Desk office hours on Tuesdays & Thursdays at 10-11 am PT/1-2 pm ET Register here.
- Submit a Support Request.
- ② Consult the Frequently Asked Questions (FAQs).
- A quick start tour is available inside the Enclave.

Orientation will be scheduled in January/ Tutorials available in the Enclave

# NCATS COLLABORATE, INNOVATE, ACCELERATE,

## **Numerous Projects**

**Numerous People** 

**Numerous Institutions** 

**Expertise &** Resources Connected

#### **140 Projects**

dium glucose co-transporter 2 inhibitor (SGLT2i) use and COVID-19 outcomes: A national retro DVID protein primary and sub-structures to interrupt protein activity followed by epidemiologica poil birdien printary and sub-subctudes to interrupt priorein activity followed by epidenhological and in-vivo of tibody response to SARS-CoV-2 in people with multiple sclerosis treated with B cell depleting to Alcohol Use and Respiratory Outcomes in COVID19 in Smoking and COVID-19 Outcomes in U.S. Adults (S. Validate a Machine Learning Model to Predict Decompensation in Patients with C Workflow Construction with Synthetic Data - Understanding non-invasive ventilation treatment failures in C NSC Cohort Charact COVID-19 in individuals with Down's S; Examining Associations between Vitamin D Status and COVID-19 in Illinitivuous with Down S of Identification of Novel COVID-19 Subphenotypes Using Temperature Tra Identification of Novel COVID-19 Subphenotypes Using Temperature Tra in evaluation of Direct Acting Anticoagulants and Dexamethasone in Patients with COVID-19 ir NSC Diabetes and Obesity Domain Team level 2 request N3C Diabetes and Obesity Domain Team level 2 request [N3C Operational] Data Ingestion and Harm .

Studying COVID-19 Remission, Recrudescence, Recurrence, and Re [N3C Operational] Implementation of Syntiegra Synthetic Data Get impact of medication on outcomes for diabetic Monocytopenia in CI Acute Kidney Injury in Pediatric COVID-19 Acute Kidney Injury in Pediatric COVID-19 Using Machine Learning to differentiate COVID-19 infection with sea OVID-19 and Percutaneous Catheterization Interventions: Modeling Risk of Senous Adverse O COVID-19 infection and mortality among individuals with didicated in the Covid | 19 infection in patients with pulmonary non-tuberculous Mycobacterium (NTM) infection: A cohr Disparities in CI Disparities in CI Disparities in CI | N3C Operational | Collaborative | resarial Network (GAN) based synthetic EHR data generation methods for enabling COVID-19 | Outcomes of Acute Pulmonary Embolism in CI | N3C Operational | Synthetic Data Validation Us | N3C Pregnancy Task Team: COVID-19 Incidence. Treatment, and Outcomes in Pregnant on Grace and other Social Determinants of Health to Disparities in Patient Outcomes in CI | Hospitalization Rates Feb-April vs May: The Effect of COVID-19 Stay-Al-Home Orders on Hemoglobin At Le evels in Diabetic Developing Dynamic Graphs for Prediction and Classification of COVID-19 Patient Trace | Covince of the professional diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated diseases in borstalizated nations with COVID-19 | Covince of participated disease Occurrence of neurological diseases in hospitalized patients with COVID-19 COVID-19 and Air ing health system in the COVID-19 pandemic: analysis of patient data to assist clinical decisior Protective Effects of Medications Against SARS-CoV2 Infection in Patients with susting Pres 1-RA) and sodium glucose or 1-RA) and sodium glucose co-transporter 2 inhibitor (SGLT2) use and COVID-19 outcomes: A multiorgan Dysfunction Syndrome and Complex Clinical Data-driven Investigation of Health Disparities in COVID-19 Outcomes: A Focus on Behavior. Investigating the impact of biases on the performance of analytical models for COVID-19 relating the impact of biases on the performance of analytical models for COVID-19 relating the process: Varying Underlying Pathophysiological Mechanisms at Different Time Points and Sorthopaedic Surgery in the National COVID Cohort Collaboration (COVID-19 Risks for Back-to-Work Portion (C Association of Department of Cardiovascular Complications of Ci Social determinants of health with regards to differential COVID-19 incidence across the Unite Use, Safety and Effectiveness of Therapies to Treat Ci Ose, Salely and Encelleres of Therapies to Treat of the severity of COVID-19 infections of individual patients by applying artificial intelligence methon (N3C immunoSuppressed/Compromised Task Team: The Impact of COVID-19 in the ISC Pt. Epidemiology of Acute and Chronic Kidney Injury Associated SARS-CoV-2 Analysis of 1 time Windows as Determining Factors for COVID-19 Patient Of mporal Lab Value Changes and Medications as Predictors of Health Outcomes for COVID-19 (N3C Operational) Phenotype and Data Acquisition Team Of Retrospective Identification of medications to treat C Adaptive and interpretable machine learning to predict COVID-19 relactory and Case-Control Studies of Medications and Their Possible Associations with COVID-19 HIV and COVID-19: Effect of Shelter-In-Place Orders on Virologic Supingates of COVID-19 in Older Adults (Eider Impact Domain Impacts of COVID-19 in Older Adults (Eider Impact Domain Impacts of COVID-19 in Older Adults (Eider Impact Clinical Outcomes for Drug Repurposing Candidates Discovered in BSL3 SARS-CoV-2 (Infectic Study Phenotype of COVID-19 in Patients with Hemophilia: A National CoN 2 infection in African Americans: "Al-based Novel Approach of Prognostic and Risk, Straiffication" 2 infection in African Americans: Al-based Novel Approach of Prognostic and Risk Stratification
2 infection in African Americans: Al-based Novel Approach of Prognostic and Risk Stratification
Clinical Characterization of Critically-ill COVID-19 Patients based on Ventilation
vide association study of COVID-19 outcomes using electronic health records and informatic re-

Predicting organ failure in patients with COVID-19

#### 1231/561 People 313 Institutions

